VBI Vaccines (VBIV) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

VBIV Stock Forecast

VBI Vaccines stock forecast is as follows: a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.

VBIV Analyst Ratings

Strong Buy

According to 2 Wall Street analysts, VBI Vaccines's rating consensus is 'Strong Buy'. The analyst rating breakdown for VBIV stock is 1 'Strong Buy' (50.00%), 0 'Buy' (0.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 09, 2022	Raymond James	Strong Buy	Strong Buy	Hold
Apr 26, 2022	Zacks Investment Research		Hold	Upgrade

Row per page

Go to

VBI Vaccines's last stock rating was published by Raymond James on Aug 09, 2022. The company gave VBIV a "Strong Buy" rating, the same as its previous rate.

VBI Vaccines Financial Forecast

VBI Vaccines Revenue Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	-	$485.00K	$293.00K	-	-	$126.00K	$81.00K	-	-	$301.00K	$164.00K	-	-	$415.00K	$574.00K	-	-	$360.00K	$178.00K	$127.00K
Avg Forecast	$10.48M	$9.29M	$7.80M	$6.55M	$4.56M	$3.88M	$3.19M	$2.85M	$5.36M	$13.25M	$929.00K	$817.00K	$1.98M	$1.29M	$704.33K	$120.00K	$137.33K	$203.67K	$481.33K	$485.00K	$407.00K	$328.25K	$631.25K	$655.25K	$729.75K	$702.67K	$489.00K	$443.33K	$161.05K	$112.27K
High Forecast	$10.48M	$9.29M	$7.80M	$6.55M	$4.56M	$3.88M	$3.19M	$2.85M	$5.36M	$13.25M	$929.00K	$817.00K	$1.98M	$1.29M	$704.33K	$120.00K	$137.33K	$203.67K	$481.33K	$485.00K	$407.00K	$328.25K	$631.25K	$655.25K	$729.75K	$702.67K	$489.00K	$443.33K	$193.26K	$134.73K
Low Forecast	$10.48M	$9.29M	$7.80M	$6.55M	$4.56M	$3.88M	$3.19M	$2.85M	$5.36M	$13.25M	$929.00K	$817.00K	$1.98M	$1.29M	$704.33K	$120.00K	$137.33K	$203.67K	$481.33K	$485.00K	$407.00K	$328.25K	$631.25K	$655.25K	$729.75K	$702.67K	$489.00K	$443.33K	$128.84K	$89.82K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	5	10	7	4	4	8	5	11	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.15%	-	-	1.05%	0.59%	-	-	0.62%	0.40%	-	-	0.63%	0.79%	-	-	0.81%	1.11%	1.13%

VBI Vaccines's average Quarter revenue forecast for Jul 23 based on 1 analysts is $929.00K, with a low forecast of $929.00K, and a high forecast of $929.00K. VBIV's average Quarter revenue forecast represents a 91.55% increase compared to the company's last Quarter revenue of $485.00K (Mar 23).

VBI Vaccines EBITDA Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	5	10	7	4	4	8	5	11	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-18.50M	$-20.27M	-	-	$-15.37M	$-20.34M	-	-	$-15.06M	$-13.59M	-	-	$-8.88M	$-3.25M	-	-	$-13.40M	$-11.47M	$-8.68M
Avg Forecast	$-10.48M	$-9.29M	$-7.80M	$-6.55M	$-4.56M	$-3.88M	$-3.19M	$-17.76M	$-5.36M	$-13.25M	$-929.00K	$-18.99M	$-9.89M	$-1.29M	$-704.33K	$-20.31M	$-137.33K	$-203.67K	$-481.33K	$-12.67M	$-407.00K	$-328.25K	$-631.25K	$-8.44M	$-729.75K	$-702.67K	$-489.00K	$-13.71M	$-10.20M	$-6.90M
High Forecast	$-10.48M	$-9.29M	$-7.80M	$-6.55M	$-4.56M	$-3.88M	$-3.19M	$-14.21M	$-5.36M	$-13.25M	$-929.00K	$-15.19M	$-7.91M	$-1.29M	$-704.33K	$-16.25M	$-137.33K	$-203.67K	$-481.33K	$-10.13M	$-407.00K	$-328.25K	$-631.25K	$-6.76M	$-729.75K	$-702.67K	$-489.00K	$-10.97M	$-8.16M	$-5.52M
Low Forecast	$-10.48M	$-9.29M	$-7.80M	$-6.55M	$-4.56M	$-3.88M	$-3.19M	$-21.31M	$-5.36M	$-13.25M	$-929.00K	$-22.79M	$-11.87M	$-1.29M	$-704.33K	$-24.38M	$-137.33K	$-203.67K	$-481.33K	$-15.20M	$-407.00K	$-328.25K	$-631.25K	$-10.13M	$-729.75K	$-702.67K	$-489.00K	$-16.45M	$-12.24M	$-8.28M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.97%	2.05%	-	-	0.76%	148.07%	-	-	1.19%	33.39%	-	-	1.05%	4.46%	-	-	0.98%	1.12%	1.26%

undefined analysts predict VBIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VBI Vaccines's previous annual EBITDA (undefined) of $NaN.

VBI Vaccines Net Income Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	5	10	7	4	4	8	5	11	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-37.42M	$-19.64M	-	-	$-25.65M	$-15.64M	-	-	$-17.79M	$-15.81M	-	-	$-8.36M	$-10.88M	-	-	$-14.91M	$-12.34M	$-8.64M
Avg Forecast	$-737.54K	$-1.23M	$-2.21M	$-2.95M	$-3.69M	$-5.41M	$-7.87M	$-18.58M	$-5.41M	$-3.44M	$-53.10M	$-19.87M	$-10.42M	$-59.00M	$-51.63M	$-21.25M	$-54.09M	$-51.63M	$-49.17M	$-14.71M	$-42.78M	$-33.19M	$-29.50M	$-9.75M	$-42.41M	$-90.96M	$-103.26M	$-14.61M	$-10.81M	$-7.27M
High Forecast	$-737.54K	$-1.23M	$-2.21M	$-2.95M	$-3.69M	$-5.41M	$-7.87M	$-14.86M	$-5.41M	$-3.44M	$-53.10M	$-15.90M	$-8.34M	$-59.00M	$-51.63M	$-17.00M	$-54.09M	$-51.63M	$-49.17M	$-11.76M	$-42.78M	$-33.19M	$-29.50M	$-7.80M	$-42.41M	$-90.96M	$-103.26M	$-11.68M	$-8.65M	$-5.82M
Low Forecast	$-737.54K	$-1.23M	$-2.21M	$-2.95M	$-3.69M	$-5.41M	$-7.87M	$-22.30M	$-5.41M	$-3.44M	$-53.10M	$-23.85M	$-12.50M	$-59.00M	$-51.63M	$-25.50M	$-54.09M	$-51.63M	$-49.17M	$-17.65M	$-42.78M	$-33.19M	$-29.50M	$-11.70M	$-42.41M	$-90.96M	$-103.26M	$-17.53M	$-12.97M	$-8.73M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.88%	1.88%	-	-	1.21%	0.29%	-	-	1.21%	0.37%	-	-	0.86%	0.26%	-	-	1.02%	1.14%	1.19%

VBI Vaccines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VBIV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

VBI Vaccines SG&A Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	5	10	7	4	4	8	5	11	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	$13.28M	$15.89M	-	-	$10.93M	$12.53M	-	-	$6.75M	$7.13M	-	-	$4.06M	$-2.48M	-	-	$3.96M	$3.42M	$3.04M
Avg Forecast	$299.87M	$265.76M	$223.25M	$187.37M	$130.58M	$110.92M	$91.24M	$81.60M	$153.35M	$379.12M	$26.58M	$23.37M	$56.63M	$36.99M	$20.15M	$3.43M	$3.93M	$5.83M	$13.77M	$13.88M	$11.64M	$9.39M	$18.06M	$18.75M	$20.88M	$20.10M	$13.99M	$12.68M	$4.61M	$3.21M
High Forecast	$299.87M	$265.76M	$223.25M	$187.37M	$130.58M	$110.92M	$91.24M	$81.60M	$153.35M	$379.12M	$26.58M	$23.37M	$56.63M	$36.99M	$20.15M	$3.43M	$3.93M	$5.83M	$13.77M	$13.88M	$11.64M	$9.39M	$18.06M	$18.75M	$20.88M	$20.10M	$13.99M	$12.68M	$5.53M	$3.85M
Low Forecast	$299.87M	$265.76M	$223.25M	$187.37M	$130.58M	$110.92M	$91.24M	$81.60M	$153.35M	$379.12M	$26.58M	$23.37M	$56.63M	$36.99M	$20.15M	$3.43M	$3.93M	$5.83M	$13.77M	$13.88M	$11.64M	$9.39M	$18.06M	$18.75M	$20.88M	$20.10M	$13.99M	$12.68M	$3.69M	$2.57M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.57%	0.28%	-	-	3.18%	3.19%	-	-	0.49%	0.61%	-	-	0.22%	-0.12%	-	-	0.31%	0.74%	0.95%

VBI Vaccines's average Quarter SG&A projection for Jul 23 is $26.58M, based on 1 Wall Street analysts, with a range of $26.58M to $26.58M. The forecast indicates a 100.08% rise compared to VBIV last annual SG&A of $13.28M (Mar 23).

VBI Vaccines EPS Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	5	5	10	7	4	4	8	5	11	15
EPS	-	-	-	-	-	-	-	-	-	-	-	$-4.34	$-0.08	-	-	$-2.98	$-0.06	-	-	$-0.07	$-0.06	-	-	$-1.50	$-0.10	-	-	$-0.15	$-0.19	$-0.22
Avg Forecast	$-0.03	$-0.05	$-0.09	$-0.12	$-0.15	$-0.22	$-0.32	$-0.53	$-0.22	$-0.14	$-2.16	$-2.27	$-2.10	$-2.40	$-2.10	$-2.40	$-2.20	$-2.10	$-2.00	$-1.80	$-1.74	$-1.35	$-1.20	$-1.88	$-1.73	$-3.70	$-4.20	$-4.60	$-0.15	$-0.16
High Forecast	$-0.03	$-0.05	$-0.09	$-0.12	$-0.15	$-0.22	$-0.32	$-0.53	$-0.22	$-0.14	$-2.16	$-2.27	$-2.10	$-2.40	$-2.10	$-2.40	$-2.20	$-2.10	$-2.00	$-1.80	$-1.74	$-1.35	$-1.20	$-1.88	$-1.73	$-3.70	$-4.20	$-4.60	$-0.12	$-0.13
Low Forecast	$-0.03	$-0.05	$-0.09	$-0.12	$-0.15	$-0.22	$-0.32	$-0.53	$-0.22	$-0.14	$-2.16	$-2.27	$-2.10	$-2.40	$-2.10	$-2.40	$-2.20	$-2.10	$-2.00	$-1.80	$-1.74	$-1.35	$-1.20	$-1.88	$-1.73	$-3.70	$-4.20	$-4.60	$-0.18	$-0.19
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.92%	0.04%	-	-	1.24%	0.03%	-	-	0.04%	0.04%	-	-	0.80%	0.06%	-	-	0.03%	1.27%	1.38%

According to undefined Wall Street analysts, VBI Vaccines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VBIV previous annual EPS of $NaN (undefined).

VBI Vaccines Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GRTS	Gritstone bio	-	-	15466.67%	Buy
VBIV	VBI Vaccines	-	-	7042.86%	Strong Buy
ALLO	Allogene Therapeutics	-	-	1274.41%	Buy
ONTX	Traws Pharma	-	-	600.00%	Buy
OCGN	Ocugen	-	-	455.56%	Buy
ANVS	Annovis Bio	-	-	278.06%	Buy
VXRT	Vaxart	-	-	233.33%	Hold
GOVX	GeoVax Labs	-	-	196.30%	Buy
ANIX	Anixa Biosciences	-	-	145.10%	Buy
BBIO	BridgeBio Pharma	-	-	93.63%	Buy
ARDX	Ardelyx	-	-	70.90%	Buy
AKRO	Akero Therapeutics	-	-	47.44%	Buy
AUPH	Aurinia Pharmaceuticals	-	-	22.58%	Buy

VBIV Forecast FAQ

Is VBI Vaccines a good buy?

Yes, according to 2 Wall Street analysts, VBI Vaccines (VBIV) is considered a 'Strong Buy'. The rating consensus is based on 1 'Strong Buy' and 0 'Buy' recommendations, accounting for 50.00% of VBIV's total ratings.

What are VBI Vaccines's analysts' financial forecasts?

VBI Vaccines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $14.48M (high $14.48M, low $14.48M), average EBITDA is $-29.389M (high $-25.837M, low $-32.94M), average net income is $-35.544M (high $-31.828M, low $-39.26M), average SG&A $414.34M (high $414.34M, low $414.34M), and average EPS is $-1.22 (high $-1.22, low $-1.22). VBIV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.12M (high $34.12M, low $34.12M), average EBITDA is $-34.122M (high $-34.122M, low $-34.122M), average net income is $-7.13M (high $-7.13M, low $-7.13M), average SG&A $976.25M (high $976.25M, low $976.25M), and average EPS is $-0.29 (high $-0.29, low $-0.29).

Did the VBIV's actual financial results beat the analysts' financial forecasts?

Based on VBI Vaccines's last annual report (Dec 2022), the company's revenue was $1.08M, which missed the average analysts forecast of $4.1M by -73.59%. Apple's EBITDA was $-81.82M, beating the average prediction of $-32.201M by 154.09%. The company's net income was $-141M, missing the average estimation of $-142M by -0.95%. Apple's SG&A was $56.12M, missing the average forecast of $117.21M by -52.12%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-9 by -93.89%. In terms of the last quarterly report (Mar 2023), VBI Vaccines's revenue was $485K, missing the average analysts' forecast of $817K by -40.64%. The company's EBITDA was $-18.499M, missing the average prediction of $-18.993M by -2.60%. VBI Vaccines's net income was $-37.422M, beating the average estimation of $-19.872M by 88.31%. The company's SG&A was $13.28M, missing the average forecast of $23.37M by -43.17%. Lastly, the company's EPS was $-4.34, beating the average prediction of $-2.265 by 91.61%